Twelve Points Wealth Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.17M Buy
3,235
+187
+6% +$64K 0.23% 85
2026
Q1
$1.07M Buy
3,048
+526
+21% +$188K 0.24% 89
2025
Q4
$822K Sell
2,522
-801
-24% -$254K 0.19% 104
2025
Q3
$938K Sell
3,323
-285
-8% -$82.7K 0.23% 104
2025
Q2
$1.01M Buy
3,608
+393
+12% +$111K 0.27% 94
2025
Q1
$1M Sell
3,215
-31
-1% -$9.15K 0.27% 89
2024
Q4
$846K Buy
3,246
+1,378
+74% +$409K 0.24% 95
2024
Q3
$602K Buy
1,868
+153
+9% +$50K 0.19% 112
2024
Q2
$536K Buy
1,715
+118
+7% +$34.7K 0.19% 114
2024
Q1
$454K Sell
1,597
-31
-2% -$9.07K 0.17% 120
2023
Q4
$469K Buy
1,628
+87
+6% +$23.7K 0.22% 116
2023
Q3
$414K Buy
1,541
+150
+11% +$37.4K 0.21% 124
2023
Q2
$309K Buy
1,391
+143
+11% +$33.2K 0.16% 137
2023
Q1
$302K Buy
1,248
+131
+12% +$32.2K 0.17% 137
2022
Q4
$293K Sell
1,117
-8
-0.7% -$2.14K 0.2% 135
2022
Q3
$254K Buy
1,125
+19
+2% +$4.61K 0.2% 142
2022
Q2
$269K Buy
1,106
+100
+10% +$24.5K 0.21% 142
2022
Q1
$243K Buy
+1,006
New +$231K 0.18% 155

Other funds holding AMGN

Twelve Points Wealth Management's AMGN Position: Q2 2026 in Review

Twelve Points Wealth Management increased its Amgen (AMGN) stake by 6.1% in Q2 2026, buying an estimated $64K and bringing the position to 3,235 shares worth $1.17M. The position accounts for 0.23% of the portfolio, ranked #85.

Twelve Points Wealth Management first reported a position in AMGN in Q1 2022 and has held it in 18 quarters since. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Twelve Points Wealth Management held 3,235 shares of Amgen worth $1.17M as of Q2 2026.
  • Twelve Points Wealth Management bought 187 Amgen shares in Q2 2026, an estimated $64K.
  • Amgen made up 0.23% of Twelve Points Wealth Management's portfolio in Q2 2026, its #85 holding.
  • Twelve Points Wealth Management first reported a position in Amgen in Q1 2022 and has held it in 18 quarters since.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Twelve Points Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.